Ionis Pharmaceuticals, Inc.
CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Last updated:

Abstract:

The present disclosure provides half duplex compounds comprising a first oligomeric compound and a second, shorter, oligomeric compound, wherein the first oligomeric compound is complementary to a target nucleic acid and the second oligomeric compound is complementary to the first oligomeric compound. In certain embodiments, the compounds disclosed herein are useful for modulating the expression of extra-hepatic target nucleic acids.

Status:
Application
Type:

Utility

Filling date:

14 Dec 2018

Issue date:

17 Dec 2020